XORTX Therapeutics Inc.
XRTX
$2.28
-$0.03-1.30%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | -135.57% | -15.71% | -582.04% | -10.65% | -521.93% |
| Total Depreciation and Amortization | -33.70% | -0.77% | 11.49% | 13.51% | -16.36% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 109.57% | 97.44% | 88.47% | 73.54% | 89.41% |
| Change in Net Operating Assets | -2,549.09% | 7.68% | 80.71% | -1.23% | -90.02% |
| Cash from Operations | -311.80% | 22.11% | 20.81% | 16.27% | -7.74% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -539.91% | -132.35% | -6,507.50% | 76.29% | -139.56% |
| Cash from Investing | -539.91% | -132.35% | -6,507.50% | 76.29% | -139.56% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | 35.19% | 3.90% | 3.96% | 3.60% | -161.80% |
| Issuance of Common Stock | -- | -- | -26.50% | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -3,997.52% | -259.65% | -21.04% | -- | -- |
| Cash from Financing | 9,679.03% | -254.14% | -42.86% | 3,572.52% | -387.64% |
| Foreign Exchange rate Adjustments | -123.70% | -172.73% | 109.61% | -127.18% | 1,180.00% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 189.42% | -6.19% | -290.51% | 116.77% | -9.88% |